Last reviewed · How we verify
ZTI-01
At a glance
| Generic name | ZTI-01 |
|---|---|
| Also known as | disodium fosfomycin, IV fosfomycin, fosfomycin disodium, fosfomycin for injection |
| Sponsor | Nabriva Therapeutics AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravenous Fosfomycin Pharmacokinetics Study (PHASE1)
- PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age) (PHASE1)
- Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections (PHASE2, PHASE3)
- 4-way Crossover QT Evaluation in Healthy Subjects (PHASE1)
- Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZTI-01 CI brief — competitive landscape report
- ZTI-01 updates RSS · CI watch RSS
- Nabriva Therapeutics AG portfolio CI